CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy (CHASE Study)
Eligibility
Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria:
* Sign informed consent;
* Between the ages of 18 and 85;
* Clinical diagnosis of pulmonary hypertension, using or planning to use pulmonary hypertension targeted drugs (including any one or more of the following: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists and prostacyclin receptor agonists).
Exclusion Criteria:
* Have a history of mental illness or drug or poison addiction, and can not sign informed consent or can not cooperate with the experimental study;
* Patients with malignant tumor and other diseases and life expectancy of less than half a year;
* Short-term (less than 2 weeks) patients taking targeted drugs for pulmonary hypertension
Primary outcome measure(s)
Incidence of clinical worsening events 1 year after enrollment — 1 year after enrollment All-cause death, Pulmonary hypertension progression associated with re-hospitalization, Progress of pulmonary hypertension disease
Trial sites (1)
Facility
City
Region
Status
Center for Respiratory and Pulmonary Vascular Diseases, Fuwai hospital, CAMS & PUMC
Beijing
China
Recruiting
More Chinese Pulmonary Vascular Disease Research Group trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.